Carmine Therapeutics
Tenzin obtained his Ph.D. in Molecular Pharmacology from New York University Medical Center. During his Ph.D., he studied the effect of perturbation of cell signaling pathways in the context of cancer and embryonic stem cells. Tenzin has co-authored 5 publications and one book chapter in the fields of RNAi and small molecule and small-biologic screening.
After his Ph.D., Tenzin did a short postdoctoral stint at the Genome Institute of Singapore, in collaboration with an industrial partner on discovering small-biologics against immunomodulating receptors. Tenzin is a Fulbright Scholar and recipient of several graduate fellowships.
This person is not in any teams
This person is not in any offices
Carmine Therapeutics
Carmine Therapeutics, headquartered in Cambridge MA, is pioneering a new class of non-viral gene therapies based on red blood cell extracellular vesicles, combined with proprietary payloads.